Findings set stage for first clinical trial of stem cell-based therapeutic approach for AMD. Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD). The protocols established by the animal study* set the stage [Read More]
Category: Research and Developments
KSI-301 Joins List of Proposed Longer Lasting Anti-VEGF Drugs
Kodiak Sciences Inc. has announced promising results from their Phase 1 clinical trial of KSI-301, a novel anti-VEGF compound for the treatment of age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Currently approved anti-VEGF drugs require several monthly “loading dosages” at the beginning of the treatment regimen. Twelve weeks after a single dose [Read More]
Bold Print May Not Be All That Helpful
A well-known standard for publishing for low vision readers has been incorporation of large print, clear fonts, and bold lettering. Now a small study has shown that bold lettering may not be as important as previously thought. A team of researchers reported in December 2018 to the newsfeed of Science Direct that increasing boldness of [Read More]
Iron Supplementation Associated With Wet AMD
A report published in Review of Optometry on November 5, 2018 announced research* showing that non-anemic patients with wet age-related macular degeneration (wAMD) who take oral iron supplements may be at risk of retinal/subretinal hemorrhage. Researchers have found that use of oral iron supplements was significantly associated with retinal/subretinal hemorrhage at baseline in patients with [Read More]
Genentech’s Faricimab for Wet AMD May Greatly Extend Time Between Injections
(Updated May 13, 2020) Genentech has announced positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD). At 52 weeks, faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated sustained vision outcomes comparable to Lucentis (ranibizumab) dosed [Read More]